Results

Total Results: 207 records

Showing results for "aspirin".

1. Protocol for Quantitative Assessment of Benefit and Harm analysis of Aspirin for primary prevention (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-balancing-harms-benefits_research.pdf
   February 01, 2014 - for 10 years, compared with no aspirin use). … Over 10 Years Per 1,000 Men Without aspirin With aspirin Age categories in years 45-54 55-64 65-74 … 10 years per 1,000 women Without aspirin With aspirin Age categories in years 45-54 55-64 65-74 75 … Aspirin for the prevention of cardiovascular disease: U.S. … 500 mg of daily aspirin and PHS which evaluated 325 mg of aspirin every alternate day and WHS which

2. Evaluation of the Benefits and Harms of Aspirin for Primary Prevention of Cardiovascular Events: A Comparison of Quantitative Approaches | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/methods-balancing-harms-benefits/research
   February 13, 2014 - Evaluation of the Benefits and Harms of Aspirin for Primary Prevention of Cardiovascular Events: A Comparison … Results The NNT and NNH for aspirin declined with increasing age because of the increase in baseline … for 10 years, compared with no aspirin use). … When we used relative weights, the Gail/NCI approach showed that aspirin caused more benefit than harm … When we weighted outcomes equally in a sensitivity analysis, the harm from aspirin was greater compared

3. Dietary-Supplements Executive (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
   April 01, 2012 - acid,65,66 clopidogrel,67 or ticlopidine68), an anticoagulant (warfarin64), or a vasodilator (cilostazol67 … acid (aspirin); CV = cardiovascular 17 from the combination of omega-3 fatty acids plus niacin … acid 500 mg daily? … The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic … acid on platelet function and plasma lipids.

4. Dietary-Supplements Surveillance (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_surveillance.pdf
   January 01, 2013 - One pragmatic trial in 19,934 women randomized to vitamin E plus aspirin versus aspirin alone for 10 … Ginkgo biloba Five RCTs investigated this supplement in combination with antiplatelet agents (acetylsalicylic … acid, clopidogrel, or ticlopidine), an anticoagulant (warfarin), or a vasodilator (cilostazol). … Ginkgo biloba Five RCTs investigated this supplement in combination with antiplatelet agents (acetylsalicylic … acid, clopidogrel, or ticlopidine), an anticoagulant (warfarin), or a vasodilator (cilostazol).

5. Treatment Strategies for Patients With Peripheral Artery Disease | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/peripheral-artery-disease-treatment/research
   May 29, 2013 - In asymptomatic PAD patients, there was no difference between aspirin and placebo for all-cause mortality … In patients with IC, one RCT suggests that aspirin may reduce MI and composite vascular events compared … Another RCT involving IC patients suggests that clopidogrel is more effective than aspirin for reducing … Clopidogrel and aspirin appear to be equivalent for prevention of nonfatal stroke, but the confidence … Conclusions From a limited number of studies, it appears that aspirin has no benefit over placebo in

6. Peripheral-Artery-Disease-Treatment Executive (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-artery-disease-treatment_executive.pdf
   May 01, 2013 - group and 5.9% in no-aspirin group. … group and 8.8% in no-aspirin group. … ) compared with aspirin for reducing nonfatal MI, but showed no difference between aspirin and dual … to aspirin alone. … Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery

7. Evidence-based Practice Center Systematic Review Protocol (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
   December 11, 2012 - Aspirin Aspirin Aspirin Intravenous antiplatelet (glycoprotein IIb/IIIa inhibitors) Upstream … Do the effectiveness and safety vary based on the dose of aspirin used? b. … plus aspirin ○ KQ 3a: Dose and duration of oral antiplatelets in combination with aspirin at different … plus aspirin • KQ 3a: Dose and duration of oral antiplatelets in combination with aspirin at different … , double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

8. Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non-ST Elevation Myocardial Infarction | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/angina-heart-attack-treatments/research-protocol
   December 13, 2012 - Aspirin Aspirin Aspirin Intravenous antiplatelet (glycoprotein IIb/IIIa inhibitors) Upstream … Do the effectiveness and safety vary based on the dose of aspirin used? … plus aspirin KQ 3a: Dose and duration of oral antiplatelets in combination with aspirin at different … plus aspirin KQ 3a: Dose and duration of oral antiplatelets in combination with aspirin at different … , double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

9. S16 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
   October 01, 2007 - Can aspirin reduce CVD in women? … Will I have trouble adhering to aspirin? … †Per 1000 patients per year taking aspirin. … Aspirin for the primary prevention of cardiovascular events in women and men. … Gastrointestinal bleeding with low-dose aspirin—what’s the risk.

10. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain_executive.pdf
    October 01, 2011 - the salicylic acid derivatives (aspirin and salsalate) a separate subgroup. … between aspirin and vs. other NSAIDs trial) salsalate in one head-to-head trial. … No trial compared aspirin or salsalate vs. other NSAIDs. 8 Table A. … Observational studies showed a similar risk of upper GI bleeding with aspirin and non-aspirin, nonselective … acid derivatives (aspirin and salsalate) are considered a separate subgroup

11. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-disposition.pdf
    June 22, 2017 - This systematic review does not mention aspirin as an acceptable VTE prophylaxis agent after major … regarding aspirin, in the context of the research questions and study eligibility. … conclusions about LMWH versus aspirin, based on available observational data. … We understand the concerns about the lack of direct comparative studies on aspirin. … aspirin, based on observational studies, were added.

12. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis—An Update of the 2006 Report. (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
    October 01, 2011 - Aspirin it is inappropriate to lump all aspirin together. … Most aspirin is used in low-dose and the GI risk is lower than it is for full dose aspirin used for … One could even argue that full dose aspirin may have less CV benefit, because at low doses, aspirin … and higher doses of aspirin up to 1500 mg daily. … We did not speculate about effects of high-dose aspirin since all of the evidence is on low- dose aspirin

13. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/osteoarthritis-pain-2006/research
    September 25, 2006 - the comparative efficacy and safety of non-opioid oral medications (selective and non-selective non-aspirin … NSAIDs, aspirin, salsalate, and acetaminophen), over-the-counter supplements (chondroitin and glucosamine

14. Achieving Health Equity in Preventive Services: Systematic Evidence Review | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/health-equity-preventive/protocol
    August 31, 2018 - to diabetes Disease specific mortality, morbidity, quality-of-life, harms of screening Aspirin … or/16-19 exp diabetes mellitus, type 2/ or prediabetic state/ exp Cardiovascular Diseases/ Aspirin … or/16-19 exp diabetes mellitus, type 2/ or prediabetic state/ exp Cardiovascular Diseases/ Aspirin … / (aspirin or "acetylsalicylic acid").ti,ab,kw. … / (aspirin or "acetylsalicylic acid").ti,ab,kw.

15. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0407_01-20-2011.pdf
    January 01, 2011 - surgery), and exercise therapy Comparator(s): KQ1/KQ2: antiplatelet therapy, antiplatelet therapy and aspirin … Does aspirin reduce the risk of adverse cardiovascular events (MI, stroke, cardiovascular death) in … Is clopidogrel more effective than aspirin in reducing adverse cardiovascular events in PAD? 3.

16. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/thromboembolism-update/research-2017
    June 22, 2017 - Most studies evaluated low molecular weight heparin (LMWH), not low-risk interventions (such as aspirin … In THR, LMWH has lower VTE and adverse event risks than unfractionated heparin; LMWH and aspirin have … LMWH and aspirin have similar risks of total PE, symptomatic DVT, and major bleeding (low SoE). … In THR, LMWH has lower VTE and adverse event risks than UFH, LMWH and aspirin have similar risks of VTE

17. Comparative Effectiveness Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - Fever;Pain Pain: 650-1000 mg up to 4g/day Peds: 10-15 mg/kg/dose up to 5 doses/day aspirin Elimination … Trials of rofecoxib vs NSAIDs Author year Aspirin permitted? … Excluded aspirin 81 mg users. 25 diclofenac 50 tid 693 52 Appendix F. … use; topical product use at the application site; history of sensitivity to any of the study drugs, acetylsalicylic … acid or other NSAID; severe, uncontrolled cardia, renal hepatic or other systemic disease; documented

18. EPC Systematic Review Protocol: Achieving Health Equity in Preventive Services: Systematic Evidence Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/health-equity-protocol.pdf
    January 01, 2020 - preventive medication Adults age 50 to 59 years with >10% 10-year CVD risk Use of low-dose aspirin … CVD); CRC incidence; disease specific mortality, morbidity, quality-of-life, harms of low dose aspirin … Aspirin use to prevent CVD and colorectal cancer: preventive medication 3. … / 29 (aspirin or "acetylsalicylic acid").ti,ab,kw. 30 exp Colorectal Neoplasms/pc [Prevention … / 29 (aspirin or "acetylsalicylic acid").ti,ab,kw. 30 exp Cardiovascular Diseases/pc [Prevention

19. Angina-Heart-Attack-Treatments Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_executive.pdf
    January 01, 2014 - Aspirin and Antiplatelet Agents In the absence of contraindications, aspirin is currently recommended … mg; high-dose aspirin ranged from 150 mg to 325 mg. 4 Figure A. … Do the effectiveness and safety vary based on the dose of aspirin used? b. … Key Points: Low-Dose Versus High-Dose Aspirin • In the postdischarge setting, high-dose aspirin was … bHRs less than 1 favor high-dose aspirin; HRs greater than 1 favor low-dose aspirin. Table L.

20. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
    June 01, 2017 - – LMWH vs. aspirin: Based primarily on a very large propensity-score-adjusted NRCS, LMWH and aspirin … N=1533) compared LMWH versus antiplatelet drug (aspirin). … Across this study set, 23 interventions were evaluated (apixaban, aspirin, aspirin plus IPC, aspirin … plus VFP were directly compared with aspirin only; aspirin plus IPC was directly compared with enoxaparin … However, one RCT of aspirin versus the combination of aspirin plus VFP did not connect to the network